What's Happening?
Regeneron, a biopharmaceutical company, is actively seeking a Senior Associate Scientist to join its Velocigene Assisted Reproductive Technology and Transgenic Biology group in Tarrytown, NY. This hybrid role focuses on expanding the company's in vitro
and in vivo gene editing capabilities. The successful candidate will be responsible for conducting CRISPR experiments, including Cas9, prime editing, and base editing. Key duties also involve building sequencing and long-read libraries, and providing support for mouse studies from injection through tissue collection. The position requires hands-on experience with cell culture techniques such as transfection, electroporation, and viral transduction, as well as molecular biology techniques like PCR, qPCR, cloning, and nucleic acid/protein handling. The role emphasizes independent work, troubleshooting, and collaboration within a team and with cross-functional partners. Regeneron aims to drive innovation in genome modification techniques and tools for therapeutic advancements through this hire.
Why It's Important?
This hiring initiative by Regeneron is significant for the U.S. biopharmaceutical industry and the broader field of genetic research. The focus on advanced gene editing technologies like CRISPR, prime editing, and base editing underscores the industry's commitment to developing novel therapeutic solutions for serious diseases. By expanding its in vitro and in vivo gene editing capabilities, Regeneron is positioning itself at the forefront of genetic medicine, which could lead to breakthroughs in treating a wide range of conditions. The demand for specialized skills in transgenic biology and molecular techniques highlights a growing need for highly trained professionals in this sector, potentially influencing academic curricula and workforce development in biotechnology hubs across the U.S. Success in these research areas could translate into new drug candidates, impacting patient care and the economic landscape of the pharmaceutical market.
What's Next?
The immediate next step for Regeneron is to fill this Senior Associate Scientist position, integrating the new hire into their Velocigene Assisted Reproductive Technology and Transgenic Biology group. Once onboarded, the scientist will contribute directly to ongoing research and development efforts in gene editing. This will involve the execution of complex experiments and the generation of data crucial for advancing therapeutic programs. The company will likely continue to invest in cutting-edge gene editing technologies and expand its research teams as new discoveries emerge and therapeutic pipelines mature. Future developments could include the progression of gene-edited therapies into preclinical and clinical trials, potentially leading to new treatments for patients and further strengthening Regeneron's market position in the competitive biopharmaceutical landscape.
Beyond the Headlines
The pursuit of advanced gene editing capabilities, as evidenced by Regeneron's hiring, carries profound ethical and societal implications. While the immediate goal is therapeutic advancement, the underlying technologies like CRISPR raise questions about genetic modification, germline editing, and the potential for unintended consequences. The development of more precise editing tools such as prime and base editing aims to mitigate some of these risks, but the broader societal debate around the boundaries of genetic intervention will continue. Furthermore, the economic accessibility of such advanced therapies, once developed, will be a critical consideration, impacting healthcare equity. The continuous innovation in this field also necessitates robust regulatory frameworks to ensure responsible research and application, shaping future public policy discussions on biotechnology and bioethics in the U.S. and globally.













